- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05849883
Bioequivalence Study of 20 mg Omeprazole Capsules in Indonesia Healthy Subject
May 8, 2023 updated by: PT Kalbe Farma Tbk
The study was conducted to investigate whether 20 mg omeprazole capsules manufactured by PT.
Dankos Farma for PT.
Hexpharm Jaya is bioequivalent to its reference product, 20 mg Losec® capsules manufactured by AstraZeneca AB, Sweden, imported by PT.
AstraZeneca Indonesia.
Study Overview
Detailed Description
Thirty six healthy subjects were given a single dose of 20 mg omeprazole capsules or 20 mg Losec® capsules with 240 mL of water.
Then the blood samples for omeprazole were drawn and analyzed using LCMS/MS.
All subjects sample plasma were analyzed for pharmacokinetic evaluation.
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
DKI Jakarta
-
Jakarta Pusat, DKI Jakarta, Indonesia, 10520
- PT Pharma Metric Labs
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
The inclusion criteria were healthy male or female subjects who/with:
- had read the subject information and signed informed consent documents
- age range from 18 - 55 years
- body mass index between 18-25 kg/m2
- had a normal electrocardiogram
- had the blood pressure within normal range (systolic 90-120 mmHg and diastolic 60-80 mmHg)
- had the heart rate within normal range (60 - 100 bpm)
- had absence of significant disease or clinically significant abnormal laboratory values on laboratory evaluation, medical history or physical examination during screening.
- accepted to use protection (condom) before any intercourse with their spouse throughout the study
Excluded from the study were:
- those who were pregnant and/or nursing women (for women).
- those with history of contraindication or hypersensitivity to omeprazole, or other proton pump inhibitor drugs or other ingredients in the drugs or a history of serious allergic reaction to any drug, a significant allergic disease, or allergic reaction.
- those with a history or presence of medical condition which might significantly influence the pharmacokinetic of the study drug, e.g. chronic gastrointestinal disease, diarrhea, gastric surgery, renal insufficiency, hepatic dysfunction or cardiovascular disease.
- those with a history or presence of any coagulation disorder or clinically significant hematology abnormalities.
- those who were using any medication (prescription or non-prescription drug, food supplement, herbal medicine), particularly the medication known to affect the pharmacokinetic of the study drug, within one week prior to the drug administration day.
- those who had participated in any clinical study within 3 months prior to the study (<90 days).
- those who had donated or lost 300 ml (or more) of blood within 3 months prior to the study.
- those who smoked more than 10 cigarettes a day
- those who were reactive to SARS CoV-2 test.
- those with a history of travelling to another city within the last 14 days
- those with a history of direct contact with a COVID-19 positive person in the subject's neighborhood
- those with a history or present of sore throat, fever (with temperature more than 37°C) or dyspnea with in the last 14 days
- those who were positive to HIV, HBsAg, and HCV tests (to be kept confidential).
- those with a history of drug or alcohol abuse within 12 months prior to screening for this study.
- those who were unlikely to comply with the protocol, e.g uncooperative attitude, inability to return for follow up visits, poor venous access.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Omeprazole 20 mg capsules
Subjects were given a single dose of 20 mg omeprazole of either formulation (test or reference) with 240 ml of water
|
Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell.
Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production
Other Names:
|
Active Comparator: Losec® 20 mg capsules
Subjects were given a single dose of 20 mg omeprazole of either formulation (test or reference) with 240 ml of water
|
Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell.
Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Geometric Mean Ratio of Cmax
Time Frame: before dosing and at 15, 30, 45, 60, 75, 90, 105 minutes, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 5, 6, 8, and 10 hours after drug administration
|
The ratio between maximum concentration of test drug and reference drug after drug administration
|
before dosing and at 15, 30, 45, 60, 75, 90, 105 minutes, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 5, 6, 8, and 10 hours after drug administration
|
Geometric Mean Ratio of AUCt
Time Frame: before dosing and at 15, 30, 45, 60, 75, 90, 105 minutes, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 5, 6, 8, and 10 hours after drug administration
|
The ratio between area under curve from 0 to 10 hours of test drug and reference drug
|
before dosing and at 15, 30, 45, 60, 75, 90, 105 minutes, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 5, 6, 8, and 10 hours after drug administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics Parameter of Cmax
Time Frame: before dosing and at 15, 30, 45, 60, 75, 90, 105 minutes, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 5, 6, 8, and 10 hours after drug administration
|
Maximum plasma concentration (Cmax)
|
before dosing and at 15, 30, 45, 60, 75, 90, 105 minutes, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 5, 6, 8, and 10 hours after drug administration
|
Pharmacokinetics Parameter of AUCt
Time Frame: before dosing and at 15, 30, 45, 60, 75, 90, 105 minutes, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 5, 6, 8, and 10 hours after drug administration
|
Area Under Curve from 0 to 10 hours (AUCt)
|
before dosing and at 15, 30, 45, 60, 75, 90, 105 minutes, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 5, 6, 8, and 10 hours after drug administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Frans D Suyatna, PT Pharma Metric Labs
- Study Director: I Gusti Putu Bagus Diana Virgo, PT Pharma Metric Labs
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Kim YK, Yoon S, Yu KS, Kim BH, Yim SV. A bioequivalence study of two omeprazole formulations in healthy male volunteers. Int J Clin Pharmacol Ther. 2016 Nov;54(11):928-934. doi: 10.5414/CP202580.
- Cederberg C, Andersson T, Skanberg I. Omeprazole: pharmacokinetics and metabolism in man. Scand J Gastroenterol Suppl. 1989;166:33-40; discussion 41-2. doi: 10.3109/00365528909091241.
- Oosterhuis B, Jonkman JH. Omeprazole: pharmacology, pharmacokinetics and interactions. Digestion. 1989;44 Suppl 1:9-17. doi: 10.1159/000200098.
- Dubcenco E, Beers-Block PM, Kim LP, Schotland P, Levine JG, McCloskey CA, Bashaw ED. A Proton Pump Inhibitor in the Reformulation Setting: Bioequivalence and Potential Implications for Long-Term Safety. Clin Transl Sci. 2017 Sep;10(5):387-394. doi: 10.1111/cts.12475. Epub 2017 Jun 15.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 10, 2020
Primary Completion (Actual)
January 14, 2021
Study Completion (Actual)
February 3, 2021
Study Registration Dates
First Submitted
February 8, 2023
First Submitted That Met QC Criteria
May 8, 2023
First Posted (Actual)
May 9, 2023
Study Record Updates
Last Update Posted (Actual)
May 9, 2023
Last Update Submitted That Met QC Criteria
May 8, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 551/STD/PML/2020
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug Use
-
University of California, Los AngelesInstituto Nacional de Psiquiatría Dr. Ramón de la FuenteCompletedDrug Use | Harmful Use
-
University of California, Los AngelesCompleted
-
Hamad Medical CorporationPrimary Health Care Corporation, QatarRecruiting
-
Umeå UniversityRegion VästerbottenNot yet recruiting
-
University of California, Los AngelesNational Institute on Drug Abuse (NIDA); Medical University of South Carolina; University of ArkansasRecruitingDrug UseUnited States
-
PT. Kimia Farma (Persero) TbkPT Pharma Metric LabsCompleted
-
PT BernofarmPT Pharma Metric LabsCompleted
-
Ain Shams UniversityRecruiting
-
Assistance Publique Hopitaux De MarseilleUnknown
-
University of California, Los AngelesNational Institutes of Health (NIH)Completed
Clinical Trials on Omeprazole 20 mg Capsules
-
Reata, a wholly owned subsidiary of BiogenAbbVieCompletedMItochondrial MyopathiesUnited States, Denmark
-
Reata, a wholly owned subsidiary of BiogenAbbVie; Friedreich's Ataxia Research AllianceActive, not recruitingFriedreich AtaxiaUnited States, Australia, Austria, Italy, United Kingdom
-
BayerCompleted
-
Livzon Pharmaceutical Group Inc.Completed
-
Wroclaw Medical UniversityActive, not recruitingEosinophilic EsophagitisPoland
-
Livzon Pharmaceutical Group Inc.Completed
-
Dow University of Health SciencesCompleted
-
HALEONCompletedGastrointestinal DiseasesCanada
-
Dr. Reddy's Laboratories LimitedCompleted
-
BayerBausch Health Americas, Inc.CompletedGastric Acid | Human Experimentation